Abstract Details

Title Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 220

Objective

Background BACKGROUND: Fingolimod is licensed in the European Union as escalation treatment for patients with relapsing-remitting multiple sclerosis (RRMS); its efficacy has been demonstrated in a large clinical trial program, but data from everyday settings are not yet available.

Design/Methods DESIGN/METHODS: Already 1800 patient in the PEARL study and 200 patients of the PANGAEA study have completed month 9 and are part of this analysis.

Results RESULTS: The populations are comparable regarding gender and age with a slight difference in disease duration (8.4 vs 5.4 years, fingolimod vs first-line). 98.8 % of the fingolimod patients but only 66.1 % of the patients with first-line therapy found their medication easy to take (easy: 5.4 vs 26.6 %; very easy 6.6 vs 20.0 %; extremely easy 86.7 vs 19.5 %, fingolimod vs first-line). Twice as many patients receiving fingolimod are overall extremely satisfied with their medication (42.2 vs 21.4 %). The relative number of sick certificates was comparable (9.5 % vs 10.2 %), the median number of days absent from work, however, was three times lower in patients receiving fingolimod (5±6.45 vs 14±26.54; days±SD).

Conclusions CONCLUSIONS: These first results suggest that patients are more satisfied with fingolimod, which is taken orally once daily, compared to injectable first-line IFN-beta and GA. This might translate to better compliance and effectiveness. . Apart from that, the lower count of sick days under fingolimod holds a chance of reducing health costs caused by MS-related sick-leave.

Authors/Disclosures
Tjalf Ziemssen, MD, FAAN (University Clinic Dresden) PRESENTER	Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.
Patrick Vollmar (Novartis Pharma)	No disclosure on file
Matthias Meergans	No disclosure on file
Ferenc M. Tracik, MD	No disclosure on file
Maria Diaz Lorente, MD (Novartis Pharma GmbH)	No disclosure on file
	No disclosure on file
Tom van Lokven	No disclosure on file
Edward Fox, MD, PhD, FAAN	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Fox has received research support from Biogen. The institution of Dr. Fox has received research support from Genentech. The institution of Dr. Fox has received research support from Celgene - BMS. The institution of Dr. Fox has received research support from Chugai. The institution of Dr. Fox has received research support from Novartis. The institution of Dr. Fox has received research support from EMD-Serono. The institution of Dr. Fox has received research support from TG Therapeutics. The institution of Dr. Fox has received research support from AbbVie. The institution of Dr. Fox has received research support from Sanofi Genzyme. The institution of Dr. Fox has received research support from AbbVie.

��ɫ��

��ɫ��